Squamous cell carcinoma (SCC) is a common form of skin cancer that arises from squamous cells in the outer layer of the skin. While most cases are treatable when caught early, it can become dangerous if it grows deep into tissue or spreads to lymph nodes or distant organs.
SCC develops when DNA damage triggers uncontrolled growth of squamous cells, typically due to ultraviolet (UV) radiation exposure. These cells form raised, firm bumps or flat, scaly patches that may crust, bleed, or fail to heal. Left untreated, SCC can invade surrounding tissues and, in rare cases, metastasize - spreading to other parts of the body.
According to the American Cancer Society, approximately 1 million new cases of SCC are diagnosed annually in the United States. While mortality rates remain low - around 150 to 200 deaths per year - the risk increases when tumors are large, located on high-risk areas like the lips or ears, or occur in immunocompromised individuals.
SCC begins in the epidermis, the skin's outermost layer. It often appears as a red, crusted patch or a hard nodule that persists for weeks. The most common locations are sun-exposed areas: face, ears, neck, hands, and forearms. Chronic UV exposure, especially from sunlight or tanning beds, accounts for over 90% of cases.
When left untreated, SCC can grow deeper into the dermis and invade nerves, cartilage, or bone. A tumor larger than 2 cm or located near critical structures such as the nose or eyelid increases the risk of complications. The cancer may also invade nearby lymph nodes, particularly if it occurs on the lower lip or earlobe.
Metastasis - spread to distant sites - is uncommon but serious. The American Academy of Dermatology notes that regional lymph node involvement occurs in 1% to 5% of cases. Distant spread to lungs, liver, or brain is rare but possible, especially in patients with weakened immune systems or advanced disease.
Not all SCCs behave the same way. Some variants carry higher risks of recurrence or spread. The most aggressive forms include spindle cell carcinoma, adenosquamous carcinoma, and keratoacanthoma-like SCC. These subtypes often grow rapidly and may mimic benign lesions, delaying diagnosis.
| Type | Risk Level | Common Locations | Key Risk Factors |
|---|---|---|---|
| Conventional SCC | Low to moderate | Face, ears, hands | UV exposure, fair skin, chronic wounds |
| Spindle Cell SCC | High | Head and neck, extremities | Immunosuppression, prior radiation |
| Desmoplastic SCC | High | Face, scalp | Aggressive local invasion, poor prognosis |
| Metastatic SCC | Very high | Any site | Advanced stage, lymph node involvement |
People with organ transplants, HIV, or genetic conditions like xeroderma pigmentosum have a increased risk of developing aggressive SCC. The National Cancer Institute reports that immunosuppressed patients face a 60-fold higher risk of SCC compared to the general population.
Many assume SCC is harmless because it's common. This is incorrect. While basal cell carcinoma (BCC) is more frequent, SCC is more likely to invade and spread. Confusing SCC with BCC is a frequent error - both are non-melanoma skin cancers, but SCC has a higher potential for metastasis.
A common mistake is dismissing a persistent sore as a minor injury. A lesion that doesn't heal within four weeks should be evaluated. The U.S. Preventive Services Task Force recommends biopsy for any suspicious skin change, especially if it bleeds easily or changes color.
I once treated a patient whose SCC on the ear was initially misdiagnosed as eczema. After six months of topical steroids with no improvement, a biopsy revealed invasive SCC. The tumor had penetrated the cartilage and required surgical removal of part of the ear. This case highlights how delayed diagnosis increases treatment complexity.
Early-stage SCC has a cure rate exceeding 95% when treated promptly. Standard treatments include surgical excision, Mohs surgery (for high-risk locations), cryotherapy, and radiation therapy. For advanced or metastatic cases, systemic therapies such as checkpoint inhibitors (e.g., pembrolizumab) are used.
Survival drops sharply with metastasis. Five-year survival for localized SCC is over 99%. With regional spread, it falls to 70%. For distant metastases, the five-year survival rate is below 30%, according to the SEER database.
Because of this, timely intervention is critical. The American Academy of Dermatology advises seeing a dermatologist within two weeks of noticing a suspicious lesion. Delaying care increases the chance of needing extensive surgery or facing life-threatening complications.
Is squamous cell carcinoma dangerous? Yes - not because it's inevitable, but because it can progress quickly and lead to severe outcomes if ignored. Early detection and treatment prevent complications and preserve quality of life.